RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:318

Acute erythroid leukemia

low confidenceDisorder

Also known as: AML M6 · Acute myeloid leukemia M6 · Erythroleukemia

Publications

16,793

Trials

80

Interventional, condition-specific

Researchers

1,398

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare unclassified acute myeloid leukemia characterized by a proliferation of immature cells exclusively of the erythroid lineage without a significant myeloblastic component. Microscopically, the cells may be undifferentiated or proerythroblastic in appearance. Patients may present with pancytopenia with fatigue, infections, and mucocutaneous bleedings, as well as weight loss, fever, and night sweats. Prognosis is poor.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (12)

AEL · FAB M6 · M6 acute myeloid leukaemia · M6 acute myeloid leukemia · acute erythroblastic leukaemia · acute erythroblastic leukemia · acute erythroid leukemia · acute myeloid leukaemia M6 · acute myeloid leukemia M6 · erythroblastic leukaemia · erythroblastic leukemia · leukemia, erythroid, malignant

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    16,793 matched papers (4,725 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    80 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

16,793

16,793 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

16,793 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

4,725 in the last 10 years · low confidence

Phrase hits: 16,793 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,398

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Song J11 papers · 2026

    Natural Products Research Center of Guizhou Province, Guiyang, 550014, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China.

    Papers in Europe PMC
  2. 02
    Li Y10 papers · 2026

    Natural Products Research Center of Guizhou Province, Guiyang, 550014, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China. Electronic address: liyanmei518@hotmail.com.

    Papers in Europe PMC
  3. 03
    Liu S10 papers · 2026

    School of Preclinical Medicine, Southwest Medical University, Luzhou 646000, China.

    Papers in Europe PMC
  4. 04
    Liu W9 papers · 2026

    Natural Products Research Center of Guizhou Province, Guiyang, 550014, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China.

    Papers in Europe PMC
  5. 05
    Wang C9 papers · 2026

    Natural Products Research Center of Guizhou Province, Guiyang, 550014, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China.

    Papers in Europe PMC
  6. 06
    Xiao X8 papers · 2026

    Natural Products Research Center of Guizhou Province, Guiyang, 550014, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China.

    Papers in Europe PMC
  7. 07
    Huang L7 papers · 2026

    Natural Products Research Center of Guizhou Province, Guiyang, 550014, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China.

    Papers in Europe PMC
  8. 08
    Ben-David Y6 papers · 2026

    Natural Products Research Center of Guizhou Province, Guiyang, 550014, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China. Electronic address: yaacovbendavid@hotmail.com.

    Papers in Europe PMC
  9. 09
    Zhang Y6 papers · 2026

    Nantong University Medical School, Nantong, China.

    Papers in Europe PMC
  10. 10
    Hu A5 papers · 2026

    State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 561113, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

80

interventional trials for this specific condition

80 interventional trials matched this specific condition name; none in our sample are currently recruiting.

Data as of 27 July 2026

80 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.2th percentile).

low confidence · 98.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

80 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Observational and natural-history studies

3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Acute erythroid leukemia" OR "AML M6" OR "Acute myeloid leukemia M6" OR "Erythroleukemia" OR "FAB M6" OR "M6 acute myeloid leukaemia" OR "M6 acute myeloid leukemia" OR "acute erythroblastic leukaemia" OR "acute erythroblastic leukemia" OR "acute myeloid leukaemia M6" OR "erythroblastic leukaemia" OR "erythroblastic leukemia" OR "leukemia, erythroid, malignant"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Acute erythroid leukemia" OR "AML M6" OR "Acute myeloid leukemia M6" OR "Erythroleukemia" OR "FAB M6" OR "M6 acute myeloid leukaemia" OR "M6 acute myeloid leukemia" OR "acute erythroblastic leukaemia" OR "acute erythroblastic leukemia" OR "acute myeloid leukaemia M6" OR "erythroblastic leukaemia" OR "erythroblastic leukemia" OR "leukemia, erythroid, malignant"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 80 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: AEL

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (16793) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T13:22:44.049Z